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ISSCR: Executive NoteISSCRBoardofDirectors andOfficersElectionResultsLeadership is a key issue in every organization, but with a rela-
tively young and fast-growing organization such as the Interna-
tional Society for Stem Cell Research (ISSCR), it is especially
important to balance continuity of leadership with the introduc-
tion of fresh thinking, as well as to reflect the interests of a global
constituency.
This year the membership elected the ISSCR’s first vice presi-
dent fromAsia,ShinyaYamanaka.Thevicepresidencyconstitutes
the first year of a 4-year commitment. As with his predecessors,
Dr. Yamanaka will serve successive one-year terms as vice presi-
dent, president elect, president, and immediate past president.
Dr. Yamanaka will take on the presidency of the ISSCR following
the ISSCR 10th Annual Meeting in 2012 in Yokohama, Japan.
In the dynamic field of stem cell research, scientists frequently
move around the globe and develop international collaborations.
Dr. Yamanaka is a good case in point. He holds dual appoint-
ments at the Center for iPS Cell Research and Application
(CiRA), Kyoto University, Japan, and at the Gladstone Institutes
in San Francisco, USA. The ISSCR’s third president, Paul Sim-
mons, started his presidential term in Australia and concluded it
12 months later in Houston, Texas. Likewise, Gordon Keller’s
presidencycoincidedwith his tenure inNewYork, but he returned
to his native Canada to become Director of the McEwen Centre
for StemCell and Regenerative Medicine at the University Health
Network, Toronto, during his term as immediate past president.
The 2010 Board of Directors Election
This year, candidates Amy Wagers (USA) and Hans Clevers
(Netherlands) were elected as the newest members of the Board
of Directors (Table 1). The Nominations Committee proposed
a third candidate, Hongkui Deng (China), be appointed as a
member of the Board of Directors in the interests of balancing
regional representation. The Executive Committee approved
that appointment. Thomas Graf (Spain) and Derek van der
Kooy (Canada) were reappointed for second 3-year terms.
The Board of Directors election is preceded by a period for
open nominations, after which the Nominations Committee
determines the final slate of candidates. Following the commit-
tee’s selection, all current active and associate members are
invited to vote. Nominations Committee Chair FionaWatt (imme-
diate past president), invited Leonard Zon, Gordon Keller, Paul
Simmons, George Daley, Irving Weissman, Elaine Fuchs, and
Fred Gage to serve on the committee this year. Voting for the
2010 election was held in February, with 26% of ISSCR’s 1422
eligible members participating.
The new board members will begin their terms following the
ISSCR 8th Annual Meeting (June 16–19) in San Francisco. Elaine
Fuchs will succeed Irving Weissman as president of the ISSCR.
Dr. Weissman will continue his leadership involvement as imme-
diate past president. Fred Gage, who served as vice president in
2009–2010, will move to the president-elect position.
Board officer positions are significant leadership roles in the
society, and as Sally Temple, treasurer, and Sir IanWilmut, clerk,
complete the first year of their 3-year terms in July, they are to becommended for their contributions to the administration and
strategic focus of the Society.
New Board Members
The incoming members bring unique expertise and perspective
to the Board of Directors, and we are happy to take this oppor-
tunity to introduce them.
Amy J. Wagers, PhD, is an Associate Professor in the Depart-
ment of Stem Cell and Regenerative Biology at Harvard Univer-
sity and an Investigator in the Section on Developmental and
Stem Cell Biology at Joslin Diabetes Center. She is a Principal
Faculty member of the Harvard Stem Cell Institute and serves
on its Executive Committee. Dr. Wagers research focuses on
defining the factors and mechanisms regulating the migration,
expansion, and regenerative potential of blood-forming and
muscle-forming stem cells. Her laboratory employs sensitive
cell-sorting approaches for direct assessment of stem cell
phenotype and function and for developing surrogate in vitro
assays that faithfully reflect stem cell potential. Dr. Wagers is
a recipient of the Burroughs Wellcome Fund Career Award, the
WM Keck Foundation Distinguished Young Scholar Award,
the NIH Innovator Award, and an Early Career Award from the
Howard Hughes Medical Institute.
The Board of Directors is particularly excited to welcome
a relatively early-career principal investigator to its ranks and
sees this as an opportunity for Dr. Wagers to represent the opin-
ions and needs of the emerging leaders in the field.
Hans Clevers, MD, PhD, is a Professor of Molecular Genetics
and the Director of the Hubrecht Institute. Dr. Clevers obtained
hisMDdegree in1984andhisPhDdegree in1985 fromtheUniver-
sity Utrecht, the Netherlands. His postdoctoral work (1986–1989)
was done with Cox Terhorst at the Dana-Farber Cancer Institute
of the Harvard University, Boston. From 1991–2002, Dr. Clevers
was a Professor of Immunology at the University Utrecht and,
since 2002, a Professor of Molecular Genetics. Since 2002, he
has been the director of the Hubrecht Institute in Utrecht.
Dr. Clevers has been a member of the Royal Netherlands
Academy of Arts and Sciences since 2000 and is the recipient
of several awards, including the Dutch Spinoza Award in 2001,
the Swiss Louis Jeantet Prize in 2004, the Memorial Sloan-Ket-
tering Katharine Berkan Judd Award in 2005, the Israeli Rabbi
Shai Shacknai Memorial Prize in 2006, and the Dutch Josephine
Nefkens Prize for Cancer Research and the German Meyenburg
Cancer Research Award in 2008. He obtained an ERC Advanced
Investigator grant in 2008. He has been Chevalier de la Legion
d’Honneur since 2005.
Dr. Clevers has been selected to serve on the ISSCR’s annual
meeting program committee twice and instrumental in helping to
facilitate the upcoming ISSCR regional meeting in Amsterdam
when the ISSCR and the Netherlands Institute of Regenerative
Medicine cohost the 4th International Symposium on ‘‘Stem
Cells, Development and Regulation,’’ October 12–14, 2010.
Hongkui Deng, PhD is a Professor of Cell Biology, and the
Associate Director of Chemical Genomics Laboratory, at PekingCell Stem Cell 6, 419–420, May 7, 2010 ª2010 ISSCR 419
Table 1. 2010 ISSCR Election for Board of Directors and Officer
Positions
New Officer Appointment
Shinya Yamanaka, MD, PhD,
Vice President
Center for iPS Cell Research &
Application (CiRA), Kyoto University,
Japan andGladstone Institutes, USA
Reappointments to the Board of Directors
Thomas Graf, PhD Center for Genomic Regulation,
Spain
Derek van der Kooy, PhD University of Toronto, Canada
New Appointments to the Board of Directors
Hans Clevers, MD, PhD Hubrecht Institute, the Netherlands
Hongkui Deng, PhD Peking University,
Peoples Republic of China
Amy Wagers, PhD Joslin Diabetes Center, USA
Elections for positions on the ISSCR Board of Directors were held in
February 2010, with the new appointments taking effect following the
ISSCR 8th Annual Meeting in San Francisco, CA, USA.
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ISSCR: Executive NoteUniversity. Dr. Deng’s laboratory works on cellular reprogram-
ming and directed differentiation of human pluripotent stem cells
into functional hepatocytes and insulin-secreting pancreatic
beta cells. Prior to coming to Peking University, Dr. Deng was
the Director of Molecular Biology at Viacell, Inc., and worked
on ex vivo expansion of human hematopoietic stem cells. From
1995 to 1997, he was an Aaron Diamond Postdoctoral fellow
with Dan R. Littman at the New York University School of Medi-
cine’s Skirball Institute, where he identified major coreceptors
for HIV entry into cells. He obtained his PhD in Immunology in
1995 from University of California, Los Angeles, where he
worked with Eli Sercarz on the function of histocompatibility
molecules in antigen presentation. Dr. Deng serves on ISSCR’s
Task Force on Unproven Stem Cell Therapies and served on
the 2007 Program Committee.
Board of Director Reappointments
Thomas Graf and Derek van der Kooy completed their first
3-year term on the Board of Directors and were reappointed
by the membership for a second term. Dr. Graf has coordinated
the Differentiation and Cancer Programme at the Center for
Genomic Regulation in Barcelona, Spain since October 2006.
Dr. van der Kooy is a Professor in the Department of Medical
Genetics and Microbiology at the University of Toronto.
Dr. Graf was responsible for bringing the very successful ISSCR420 Cell Stem Cell 6, 419–420, May 7, 2010 ª2010 ISSCR7th Annual Meeting to Barcelona in 2009. Dr. van der Kooy will
assist the Board in bringing the Annual Meeting to Canada for
the second time when Toronto hosts the ISSCR 9th Annual
Meeting in 2011.
We would like to thank outgoing board member Ron McKay
(USA) for his valuable contributions to the society over the past
six years. Fiona Watt (UK) also completed a 6-year term on the
Board but will continue to be a critical resource as she begins
a 3-year ex officio term. Drs. McKay and Watt will provide addi-
tional input to the society through their involvement in commit-
tees and other initiatives from which we will continue to benefit.New Officer
Dr. Yamanaka’s appointment as vice president is the only new
officer appointment this year. Renowned for his paradigm-shift-
ing work generating first mouse and then human induced plurip-
otent stem cells (iPSCs), Dr. Yamanaka needs little introduction
to the stem cell community. He first widely presented his then-
unpublished data on mouse iPSCs at the 4th ISSCR Annual
Meeting in Toronto, Canada, in 2006. In his joint position as the
Director of the Center for iPS Cell Research and Application
(CiRA), Institute for Integrated Cell-Material Sciences at Kyoto
University, and Senior Investigator at the Gladstone Institutes
in San Francisco, Dr. Yamanaka now actively conducts iPSC
research with two dozen regenerative medicine researchers
and students.
Looking forward to his new role on the ISSCR Board of Direc-
tors, Dr. Yamanaka notes ‘‘important roles of the ISSCR are to
provide the latest and hottest scientific findings through its
Annual Meetings, and to serve as a world opinion leader in
stem cell research, application, ethics, and policy. I hope to
advance all of these roles of the ISSCR. In particular, I would
like to encourage authors to present unpublished results at
Annual Meetings, and to promote internationality of the ISSCR.’’
Indeed, the leadership of the ISSCR is constantly on the
lookout for the buzz of new and unanticipated discovery that
Dr. Yamanaka created with his presentation in Toronto.
Dr. Yamanaka’s research immediately gripped the imagination
of the 2200 scientists gathered in the plenary session that day,
and the excitement around the possibilities of cell fate reprog-
ramming and lineage conversion has continued to expand
with each Annual Meeting since 2006. As the ISSCR prepares
to return to Toronto for its 2011 meeting, Dr. Yamanaka has
set the challenge—to present new findings that have the poten-
tial to again transform the stem cell field.Nancy R. Witty
ISSCR Executive Director
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